Endostatin attenuates PDGF-BB- or TGF- β 1-induced HSCs activation via suppressing RhoA/ROCK1 signal pathways [Erratum]

Ren H, Li Y, Chen Y, Wang L. *Drug Des Devel Ther.* 2019; 13:285–290.

On page 289, Figure 4 and Notes should read as follows:

Figure 4 Endostatin inhibits the expression of α -SMA, RhoA, and ROCK1 at mRNA level.

Notes: Transcript levels of α -SMA, RhoA, and ROCK1 were analyzed by RT-PCR (A–C). Endostatin significantly suppressed the expressions of α -SMA, RhoA, and ROCK1 at mRNA level in HSC-T6 cells. Data are expressed as mean $\pm$ SD. * P <0.05, ** P <0.01 (n =3 per group).

Abbreviations: α -SMA, α -smooth muscle actin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSC, hepatic stellate cell; RhoA, ras homolog gene family, member A; ROCK1, Rho-associated protein kinase 1; RT-PCR, real-time PCR.

Drug Design, Development and Therapy**Dovepress****Publish your work in this journal**

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>